All the latest packaging trends for life sciences, all at PACK EXPO East
Explore new packaging solutions for life sciences, all in one convenient location at PACK EXPO East, March 18 – 20 in Philadelphia.

This FDA vote was personal

Committee member who recommended biosimilar had own experience with costly drugs.

Talk about first hand knowledge.

The Washington Post's Wonkblog recently profiled Randy Hillard.

The Michigan State University psychiatry professor was diagnosed with stage four stomach cancer in 2010, and given less than a year to live.

But, for four years a once-every-three-weeks infusion of Herceptin, a breast cancer drug approved to treat some types of stomach cancer, has kept in him alive – at the tune of $1 million, with about $100,000 of it being paid for himself.

“I can barely afford that, and I’m a doctor,” he told them.

Hillard, however, is also a member of the FDA committee that recently recommended approval of the what could be the U.S' first biosimilar. Biosimilars are basically generic versions of biologics.

“Really, truly, we are betting our lives on these new biosimilars,” Hillard said.

As the blog post points out, the U.S. has had generic versions of drugs for years, making the cost to consumers lower. But, if the FDA takes the committees recommendation and approves the country's first biosimilar, it will open up a whole new category of lower-cost drugs to patients.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts
Discover the right packaging solutions for life sciences in Philadelphia
Explore innovative packaging and supply chain solutions for the life sciences at the largest PACK EXPO East in history, March 18–20. Get ideas from 400+ top exhibitors and connect with colleagues and industry experts—all in one convenient location!
Read More
Discover the right packaging solutions for life sciences in Philadelphia